JPWO2020173935A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020173935A5 JPWO2020173935A5 JP2021549575A JP2021549575A JPWO2020173935A5 JP WO2020173935 A5 JPWO2020173935 A5 JP WO2020173935A5 JP 2021549575 A JP2021549575 A JP 2021549575A JP 2021549575 A JP2021549575 A JP 2021549575A JP WO2020173935 A5 JPWO2020173935 A5 JP WO2020173935A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- hydrogen
- salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
Claims (19)
各R1は、独立して、ハロゲン、C1-3アルキルおよび-NH2からなる群から選択され、
nは0、1、2または3であり、
R10は、水素、ハロゲン、C1-3アルキルおよび-NH2からなる群から選択され、
R2およびR3は、独立して、水素、ハロゲン、-OH、-C1-4アルキレン-Rq、-NRwRq、-NHC(O)NRwRq、-C(O)NRwRq、-C(O)ORq、-S(O)2NRwRqおよび-NRwS(O)2Rqからなる群から選択されるか、
またはR2およびR3は、これらが結合している原子と一緒になって、1個もしくは複数の同じもしくは異なるRtで置換されていてもよい5~6員のヘテロアリールを形成し、
Rwは、水素、C1-4アルキル、C3-6シクロアルキル、-OH、-OC1-4アルキルおよび-NH2からなる群から選択され、
Rqは、水素、C1-4アルキル、C3-6シクロアルキル、-OH、-OC1-4アルキルおよび-NH2からなる群から選択され、
Rtは、C1-4アルキル、C3-6シクロアルキル、-OH、-OC1-4アルキルおよび-NH2からなる群から選択され、
R4は-N(Rx)-または-O-であり、
Rxは、水素、C1-4アルキル、-OH、-OC1-4アルキルおよび-C1-5アルキレン-O-Ry1からなる群から選択され、
Ry1は、水素、C1-4アルキルおよび-NH2からなる群から選択され、
R5は、水素、C1-4アルキル、-OH、-OC1-4アルキルおよび-C1-5アルキレン-O-Ry2からなる群から選択され、
Ry2は、水素、C1-4アルキルおよび-NH2からなる群から選択され、
R6は水素またはC1-3アルキルであり、
R7は、-Ra-Cyおよび-Ra-Rbからなる群から選択されるか、
またはR6およびR7は、これらが結合している窒素と一緒になって、5~13員のヘテロシクリルもしくは5~13員のヘテロアリールを形成し、前記ヘテロシクリルもしくはヘテロアリールは、1個もしくは複数の同じもしくは異なるRbで置換されており、
Raは、共有結合、-C1-5アルキレン-および-C1-3アルキレン-Rc-C1-3アルキレン(NH)CH2-からなる群から選択され、
Rcは、共有結合、アリーレン、C5-14-カルボシクレン、5~13員のヘテロアリーレンおよび5~13員のヘテロシクレンからなる群から選択され、
Cyは、アリール、C5-14-カルボシクリル、5~13員のヘテロアリールおよび5~13員のヘテロシクリルからなる群から選択され、Cyは、-Ra1-Rbまたは-Ra1-Cy’で置換されており、Cyは、1個または複数の同じまたは異なるRbでさらに置換されていてもよく、
Cy’は、アリール、5~9員のヘテロアリールおよび5~9員のヘテロシクリルからなる群から選択され、Cy’は、1個または複数の同じまたは異なるRbで置換されており、
Ra1は共有結合または-C1-5アルキレン-であり、
Rbは、水素、C2-3アルキニル、C1-4アルキル、-OH、-OC1-4アルキル、-NH2、-C(O)NH2および-C1-5アルキレン-O-C1-5アルキルからなる群から選択される)
またはその塩。 Compounds of Formula (I)
each R 1 is independently selected from the group consisting of halogen, C 1-3 alkyl and —NH 2 ;
n is 0, 1, 2 or 3;
R 10 is selected from the group consisting of hydrogen, halogen, C 1-3 alkyl and —NH 2 ;
R 2 and R 3 are independently hydrogen, halogen, —OH, —C 1-4 alkylene-R q , —NR w R q , —NHC(O)NR w R q , —C(O)NR is selected from the group consisting of wRq , -C(O) ORq , -S(O ) 2NRwRq and -NRwS (O) 2Rq ;
or R 2 and R 3 together with the atoms to which they are attached form a 5- to 6-membered heteroaryl optionally substituted with one or more of the same or different R t ;
R w is selected from the group consisting of hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, —OH, —OC 1-4 alkyl and —NH 2 ;
R q is selected from the group consisting of hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, —OH, —OC 1-4 alkyl and —NH 2 ;
R t is selected from the group consisting of C 1-4 alkyl, C 3-6 cycloalkyl, —OH, —OC 1-4 alkyl and —NH 2 ;
R 4 is -N(R x )- or -O-,
R x is selected from the group consisting of hydrogen, C 1-4 alkyl, —OH, —OC 1-4 alkyl and —C 1-5 alkylene-OR y1 ;
R y1 is selected from the group consisting of hydrogen, C 1-4 alkyl and —NH 2 ;
R 5 is selected from the group consisting of hydrogen, C 1-4 alkyl, —OH, —OC 1-4 alkyl and —C 1-5 alkylene-OR y2 ;
R y2 is selected from the group consisting of hydrogen, C 1-4 alkyl and —NH 2 ;
R 6 is hydrogen or C 1-3 alkyl;
R 7 is selected from the group consisting of -R a -Cy and -R a -R b ;
or R 6 and R 7 together with the nitrogen to which they are attached form a 5-13 membered heterocyclyl or a 5-13 membered heteroaryl, wherein said heterocyclyl or heteroaryl is one or more is substituted with the same or different R b of
R a is selected from the group consisting of a covalent bond, —C 1-5 alkylene- and —C 1-3 alkylene-R c —C 1-3 alkylene(NH)CH 2 —;
R c is selected from the group consisting of covalent bond, arylene, C 5-14 -carbocyclene, 5-13 membered heteroarylene and 5-13 membered heterocyclene;
Cy is selected from the group consisting of aryl, C 5-14 -carbocyclyl, 5-13 membered heteroaryl and 5-13 membered heterocyclyl, Cy is —R a1 —R b or —R a1 —Cy′ is substituted, and Cy is optionally further substituted with one or more of the same or different R b ;
Cy' is selected from the group consisting of aryl, 5-9 membered heteroaryl and 5-9 membered heterocyclyl, Cy' is substituted with one or more of the same or different Rb ;
R a1 is a covalent bond or -C 1-5 alkylene-,
R b is hydrogen, C 2-3 alkynyl, C 1-4 alkyl, —OH, —OC 1-4 alkyl, —NH 2 , —C(O)NH 2 and —C 1-5 alkylene-OC 1-5 alkyl)
Or its salt.
nが0、1または2である、
請求項1に記載の化合物またはその塩。 each R 1 is -Cl or -F;
n is 0, 1 or 2;
A compound according to claim 1 or a salt thereof.
請求項2に記載の化合物またはその塩。 n is 0;
A compound according to claim 2 or a salt thereof.
請求項1に記載の化合物またはその塩。 R 10 is selected from the group consisting of hydrogen and —NH 2 ;
A compound according to claim 1 or a salt thereof.
請求項4に記載の化合物またはその塩。 R 10 is hydrogen;
A compound according to claim 4 or a salt thereof.
R3が水素である、
請求項1に記載の化合物またはその塩。 R 2 is —OH,
R 3 is hydrogen,
A compound according to claim 1 or a salt thereof.
Rxが水素またはC1-4アルキルである、
請求項1に記載の化合物またはその塩。 R 4 is -N(R x )- or -O-,
R x is hydrogen or C 1-4 alkyl,
A compound according to claim 1 or a salt thereof.
Rxが、水素、C1-2アルキルおよび-OCH3からなる群から選択される、
請求項1に記載の化合物またはその塩。 R 4 is -N(R x )- or -O-,
R x is selected from the group consisting of hydrogen, C 1-2 alkyl and —OCH 3 ;
A compound according to claim 1 or a salt thereof.
請求項1に記載の化合物またはその塩。 R5 is hydrogen,
A compound according to claim 1 or a salt thereof.
R7が-Ra-Cyである、
請求項1に記載の化合物またはその塩。 R 6 is hydrogen or C 1-3 alkyl,
R 7 is -R a -Cy,
A compound according to claim 1 or a salt thereof.
請求項1に記載の化合物またはその塩。 R6 and R7 , together with the nitrogen to which they are attached, contain one or more additional nitrogen heteroatoms substituted with one or more of the same or different Rb5 forming a ~13-membered heterocyclyl,
A compound according to claim 1 or a salt thereof.
請求項1に記載の化合物またはその塩。 R a is a covalent bond or -C 1-4 alkylene-,
A compound according to claim 1 or a salt thereof.
Rcが、共有結合、アリーレン、単環式C5-7-カルボシクレン、ヘテロ原子として少なくとも1個の窒素を有する単環式5~7員のヘテロアリーレンおよびヘテロ原子として少なくとも1個の窒素を有する単環式5~7員のヘテロシクレンからなる群から選択される、
請求項1に記載の化合物またはその塩。 R a is —C 1-2 alkylene-R c —C 1-2 alkylene(NH)CH 2 —,
R c is a covalent bond, arylene, monocyclic C 5-7 -carbocyclene, monocyclic 5- to 7-membered heteroarylene having at least one nitrogen as heteroatom and at least one nitrogen as heteroatom selected from the group consisting of monocyclic 5- to 7-membered heterocyclenes;
A compound according to claim 1 or a salt thereof.
Cy’が、アリール、5~9員のヘテロアリールおよび5~9員のヘテロシクリルからなる群から選択され、前記アリール、ヘテロアリールおよびヘテロシクリルが、1個または複数の同じまたは異なるRbで置換されており、
Ra1が共有結合または-C1-4アルキレン-である、
請求項1に記載の化合物またはその塩。 Cy is selected from the group consisting of aryl and 5- to 13-membered heteroaryl, wherein said aryl and heteroaryl are -R a1 -R b or -R a1 -Cy' and one or more of the same or different R b is replaced with
Cy' is selected from the group consisting of aryl, 5-9 membered heteroaryl and 5-9 membered heterocyclyl, wherein said aryl, heteroaryl and heterocyclyl are substituted with one or more of the same or different R b cage,
R a1 is a covalent bond or -C 1-4 alkylene-,
A compound according to claim 1 or a salt thereof.
請求項1に記載の化合物またはその塩。 R b is selected from the group consisting of hydrogen, C 1-3 alkyl, —OH and —OC 1-3 alkyl;
A compound according to claim 1 or a salt thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19159299.7 | 2019-02-26 | ||
EP19159299 | 2019-02-26 | ||
PCT/EP2020/054897 WO2020173935A1 (en) | 2019-02-26 | 2020-02-25 | New isoindolinone substituted indoles and derivatives as ras inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022523201A JP2022523201A (en) | 2022-04-21 |
JPWO2020173935A5 true JPWO2020173935A5 (en) | 2023-03-03 |
JP7426398B2 JP7426398B2 (en) | 2024-02-01 |
Family
ID=65598476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021549575A Active JP7426398B2 (en) | 2019-02-26 | 2020-02-25 | Novel isoindolinone substituted indoles and derivatives as RAS inhibitors |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220144810A1 (en) |
EP (1) | EP3931188B1 (en) |
JP (1) | JP7426398B2 (en) |
CN (1) | CN113474340A (en) |
WO (1) | WO2020173935A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
AU2022250712A1 (en) | 2021-03-31 | 2023-10-05 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
CN115232114B (en) | 2021-04-23 | 2023-12-19 | 上海领泰生物医药科技有限公司 | SOS1 degradation agent and preparation method and application thereof |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
TW202334136A (en) * | 2021-11-03 | 2023-09-01 | 美商傳達治療有限公司 | Pi3kα inhibitors and methods of making and using the same |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970121B1 (en) | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
BR112016008016B8 (en) | 2013-10-10 | 2023-09-26 | Araxes Pharma Llc | kras g12c inhibitory compounds, pharmaceutical composition comprising said compounds, methods for regulating the activity and for preparing a kras, hras or nras g12c mutant protein, method for inhibiting the proliferation of a population of cells and therapeutic uses of said compounds |
AR102094A1 (en) | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | KRAS PROTEIN INHIBITORS WITH A G12C MUTATION |
EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
CA2993013A1 (en) | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
KR20180063895A (en) | 2015-10-21 | 2018-06-12 | 오츠카 세이야쿠 가부시키가이샤 | Benzolactam compounds as protein kinase inhibitors |
WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
CN110312711A (en) * | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | Heterocyclic compound and its application method as RAS inhibitor |
CR20190338A (en) | 2016-12-22 | 2019-09-09 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2021148581A1 (en) * | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
-
2020
- 2020-02-25 WO PCT/EP2020/054897 patent/WO2020173935A1/en unknown
- 2020-02-25 EP EP20707599.5A patent/EP3931188B1/en active Active
- 2020-02-25 JP JP2021549575A patent/JP7426398B2/en active Active
- 2020-02-25 US US17/430,011 patent/US20220144810A1/en active Pending
- 2020-02-25 CN CN202080016480.4A patent/CN113474340A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2468021C2 (en) | Heterocyclic compounds and their application | |
JP2018528261A5 (en) | ||
JP2005523922A5 (en) | ||
JP2019529518A5 (en) | ||
JP2004514663A5 (en) | ||
JP2015532295A5 (en) | ||
JP2005524631A5 (en) | ||
JP2008536807A5 (en) | ||
JPWO2020173935A5 (en) | ||
JP2011509309A5 (en) | ||
JP2020097577A5 (en) | ||
JP2020506951A5 (en) | ||
JPWO2020243415A5 (en) | ||
CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives | |
JPWO2019195124A5 (en) | ||
JP2004525140A5 (en) | ||
JP2020530007A5 (en) | ||
JP2007505044A5 (en) | ||
JP2006503805A5 (en) | ||
JP2004523478A5 (en) | ||
KR890006228A (en) | Polyamine Derivatives as Antitumor Agents | |
KR101010871B1 (en) | Cyanoguanidine prodrugs | |
KR920016418A (en) | NMDA antagonist | |
JP2010535203A5 (en) | ||
RU2004111787A (en) | RETINOID AGONISTS (1), ALKYL UREA DERIVATIVES |